Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion James PhillipsNovember 15, 2021
Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVID James PhillipsNovember 1, 2021
Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify a Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide) James PhillipsOctober 25, 2021
Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion James PhillipsOctober 4, 2021
Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx-99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections James PhillipsSeptember 28, 2021
Revelation Biosciences a Life Sci. Co. Developing Therapeutics & Diag. for Respiratory Viral Infections Including COVID-19 to Become Publicly Traded through a Merger with Petra Acquisition Inc James PhillipsAugust 30, 2021
Revelation Biosciences Inc. Announces Results of Phase 1 Clinical Study of REVTx‑99, an Experimental Therapy for the Prevention of Respiratory Viral Infection James PhillipsMay 5, 2021
Revelation Biosciences Inc. to Present at BIO CEO & Investor Digital Conference James PhillipsFebruary 11, 2021
Revelation Biosciences Inc. Completes Dosing of Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase 1 Clinical Study of REVTx‑99 James PhillipsFebruary 3, 2021
Revelation Biosciences Inc. Announces Closing of $4.4 Million in Series A-1 Financing James PhillipsFebruary 1, 2021
Curt LaBelle, M.D. Appointed to Revelation Biosciences, Inc. Board of Directors James PhillipsJanuary 11, 2021
Revelation Biosciences Inc. Announces $9.1 Million Common Stock and Series A Financing James PhillipsJanuary 5, 2021
Revelation Biosciences Inc. Announces the Start of a Phase 1 Clinical Study for REVTx‑99, an Experimental Treatment for Respiratory Viral Infection, Including COVID‑19 James PhillipsNovember 16, 2020
Revelation Biosciences Inc. Receives TGA Acknowledgment to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19 James PhillipsOctober 7, 2020
Revelation Biosciences Inc. Receives Approval to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19 James PhillipsOctober 1, 2020
